Some factors affecting the neuron blocking action of guanethidine, xylocholine, bretylium and debrisoquin.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001949:Bretylium Compounds / Q000494:pharmacology*; D002794:Choline / Q000494:pharmacology*; D003647:Debrisoquin / Q000494:pharmacology; D004987:Ethers / Q000494:pharmacology; D006145:Guanethidine / Q000494:pharmacology*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D009638:Norepinephrine / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000187:drug effects; D013565:Sympatholytics; D014992:Xylenes / Q000494:pharmacology
D000959:Antihypertensive Agents; D001949:Bretylium Compounds; D004987:Ethers; D007546:Isoquinolines; D013565:Sympatholytics; D014992:Xylenes; D002794:Choline; D003647:Debrisoquin; D009638:Norepinephrine; D006145:Guanethidine